@article {3141228,
	title = {Fragile sites are preferential targets for integrations of MLV vectors in gene therapy},
	journal = {Gene Therapy},
	volume = {13},
	year = {2006},
	pages = {1057-1059},
	abstract = {Following gene therapy of SCID-X1 using murine leukemia virus (MLV) derived vector, two patients developed leukemia owing to an activating vector integration near the LMO2 gene. We found that these integrations reside within FRA11E, a common fragile site known to correlate with chromosomal breakpoints in tumors. Further analysis showed that fragile sites attract a nonrandom number of MLV integrations, shedding light on its integration mechanism and risk-to-benefit ratio in gene therapy.},
	author = {Bester AC. and Schwartz M. and Schmidt M. and Garrigue A. and Hacein-Bey-Abina S. and Cavazzana-Calvo M. and Ben-Porat N. and Kalle CV. and Fischer A. and Kerem B.}
}
